Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ASTX295 |
Synonyms | |
Therapy Description |
ASTX295 is an inhibitor of murine double minute 2 (MDM2; HDM2) that binds to Mdm2 and inhibits proteasomal degradation of Tp53 by Mdm2, thereby restoring wild-type Tp53 and potentially leading to induction of apoptosis in tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ASTX295 | ASTX 295|ASTX-295 | MDM2 Inhibitor 23 | ASTX295 is an inhibitor of murine double minute 2 (MDM2; HDM2) that binds to Mdm2 and inhibits proteasomal degradation of Tp53 by Mdm2, thereby restoring wild-type Tp53 and potentially leading to induction of apoptosis in tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03975387 | Phase Ib/II | ASTX295 | Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53 | Active, not recruiting | USA | 0 |